Teva Reports Real-World Benefits of AUSTEDO for Huntington’s Disease Chorea
PARSIPPANY, N.J. and TEL AVIV, Israel, June 5, 2026 Teva Pharmaceuticals announced new real-world data demonstrating that treatment with...
Patient Reported Outcomes
Advertisement
Jazz Highlights New Xywav Data Across Narcolepsy and Idiopathic Hypersomnia
DUBLIN, Ireland, June 4, 2026 Jazz Pharmaceuticals has announced the presentation of an extensive portfolio of new clinical and...
Teva Reports New AUSTEDO Data in Huntington’s Chorea
PARSIPPANY, N.J. and TEL AVIV, Israel, June 5, 2026 Teva Pharmaceuticals has presented new real-world evidence demonstrating that treatment...
Neurocrine Defines TDIS Threshold for TD Treatment Impact
SAN DIEGO, California, April 29, 2026 Neurocrine Biosciences announced the publication of new peer-reviewed research in The Journal of...
Advertisement
